Growth-oriented businesses can make excellent additions to a well-diversified portfolio.
Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.
Zenas is a Bristol Meyers Squibb-backed pharma company that is about to go public. Its treatment provides solid differentiation that could rival competitors.
Amgen AMGN stock has risen 19.6% in the past six months compared with an increase of 12.4% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below.AMGN...
/Gilead%20Sciences%2C%20Inc_%20pills-by%20%20Marc%20Bruxelle%20via%20Shutterstock.jpg)
Despite Gilead Sciences' underperformance relative to the Dow Jones Industrial Average over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.
/AMGEN%20Inc_%20logo%20on%20meds-by%20Melnikov%20Dmitriy%20via%20Shutterstock.jpg)
Amgen has surpassed the Nasdaq recently, and analysts are cautiously optimistic about its future potential.
These stocks are the A-team for income investors.
A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio.
Investors seeking reliable dividend growth want to start with these two members of the Dow Jones Industrial Average.
Amgen has many growth opportunities ahead, and it also pays a fairly high dividend.